Serological responses to revaccination against HBV in HIV-positive patients born in the era of nationwide neonatal HBV vaccination
Journal
Liver International
Journal Volume
38
Journal Issue
11
Pages
1920-1929
Date Issued
2018
Author(s)
Chen G.-J.
Yang S.-P.
Liu W.-C.
Su Y.-C.
Abstract
Background: Serological responses to revaccination against hepatitis B virus (HBV) are unclear in HIV-positive adults who had undergone neonatal HBV vaccination and whose antibodies against HBV had waned in the era of combination antiretroviral therapy (cART). Methods: Between 2000 and 2017, 666 HIV-positive men who have sex with men (MSM) who were born after 1986, when nationwide neonatal HBV vaccination programme was implemented in Taiwan, were included for analyses. A serological response was defined when a hepatitis B surface antibody (anti-HBs) titre ?10?mIU/mL was measured 4-24?weeks after the third dose of HBV vaccination. Results: During the study period, 295 (48.7%) HIV-positive MSM (mean age, 23.2?years) who had lost HBV seroprotection were eligible for revaccination; 171 (58.0%) received at least 1 dose (20-μg) of HBV vaccine and 116 (39.3%) completed the 3-dose schedule. The serological response rate to 3 doses of HBV revaccination was 74.0% and the rate of high-titre response (anti-HBs titre ?100?mIU/mL) was 46.0%. The CD4 count before the first dose (per 50-cell/μL increment, adjusted odds ratio, 1.14; 95% confidence interval, 1.01-1.29) was positively associated with the serological response. The incident rate of HBV infection was 9.2 per 1000?person-years of follow-up among the patients who were non-responders after revaccination. Conclusions: Despite HBV vaccination in the neonatal period, the serological response rate to HBV revaccination in HIV-positive MSM was modest and could wane rapidly. Regular testing of anti-HBs should be integrated into the HIV care despite cART containing HBV-active agents. ? 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
SDGs
Other Subjects
hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; lamivudine; recombinant hepatitis B vaccine; tenofovir disoproxil; hepatitis B surface antigen; hepatitis B vaccine; virus antibody; adult; antibody titer; antiretroviral therapy; Article; CD4 lymphocyte count; cohort analysis; hepatitis B; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; major clinical study; male; men who have sex with men; observational study; retrospective study; revaccination; serology; Taiwan; treatment response; young adult; blood; complication; epidemiology; hepatitis B; Hepatitis B virus; Human immunodeficiency virus infection; immunology; male homosexuality; vaccination; Adult; Antibodies, Viral; CD4 Lymphocyte Count; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; HIV Infections; Homosexuality, Male; Humans; Male; Retrospective Studies; Taiwan; Vaccination; Young Adult
Publisher
Blackwell Publishing Ltd
Type
journal article